Brief Summary
Malignantcancerous, may grow and spread to other areas of the body pleural mesothelioma (MPM) is a rare cancera disease where abnormal cells split without control and spread to other nearby body tissue and/or organs of the lung lining caused by exposure to asbestos. MPM is regarded as one of the most aggressive solid tumours, with limited treatment options and poor prognosisto predict how a disease/condition may progress and what the outcome might be. Emerging MPM treatment options are of particular interest in Australia where the incidence of MPM is among the highest in the world. One such emerging treatment involves the injection of chemotherapeutic agents into the aorta, where they perfuse directly into the vessels which supply the pleural lining. This approach, termed transarterial chemoperfusion, allows a high concentration of chemotherapya cancer treatment that uses drugs to kill or slow the growth of cancer cells, while minimising damage to healthy cells to be delivered directly to the cancer. This study is investigating the safety and effectiveness of transarterial chemoperfusion for the treatment of patients with MPM. We will evaluate tumoura tissue mass that forms from groups of unhealthy cells response, symptoms, quality of lifethe overall well-being of a person diagnosed with cancer, encompassing both physical and emotional aspects of health, progression free survival and overall survival.
Intervention/Treatment
- Transarterial chemoperfusion.
- Drug: Cisplatin.
- Drug: Methotrexate.
- Drug: Gemcitabine.
Inclusion Criteria
- Histologically or cytologically confirmed MPM.
- Tumour/s assessed as inoperable or refuses surgerytreatment involving removal of cancerous tissue and/or tumours and a margin of healthy tissue around it to reduce recurrence.
- The predominant burden of disease lies in an arterial distribution which is accessible for transarterial chemoperfusion treatment.
- Failure to respond to first line standard of care chemotherapy.
- Have measurable disease, by computed tomography (CT) as per modified Response Evaluation Criteria in Solid Tumours (RECIST) for mesothelioma.
- Ability to understand and the willingness to sign a written informed consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment. document.
- Must be willing and able to comply with scheduled visits, treatment schedule, laboratory tests, imagingtests that create detailed images of areas inside the body studies, and other requirements of the study.
- An ECOG performance status score <3.
- Patient is expected to survive and be available for follow up for at least 12 months.
- Patients must have private health insurance to be included in this trial and eligible for treatment at The Wesley Hospital.